title: Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.
abstract: A workshop was convened to discuss best practices for the assessment of drug-induced liver injury (DILI) in clinical trials. In a breakout session, workshop attendees discussed necessary data elements and standards for the accurate measurement of DILI risk associated with new therapeutic agents in clinical trials. There was agreement that in order to achieve this goal the systematic acquisition of protocol-specified clinical measures and lab specimens from all study subjects is crucial. In addition, standard DILI terms that address the diverse clinical and pathologic signatures of DILI were considered essential. There was a strong consensus that clinical and lab analyses necessary for the evaluation of cases of acute liver injury should be consistent with the US Food and Drug Administration (FDA) guidance on pre-marketing risk assessment of DILI in clinical trials issued in 2009. A recommendation that liver injury case review and management be guided by clinicians with hepatologic expertise was made. Of note, there was agreement that emerging DILI signals should prompt the systematic collection of candidate pharmacogenomic, proteomic and/or metabonomic biomarkers from all study subjects. The use of emerging standardized clinical terminology, CRFs and graphic tools for data review to enable harmonization across clinical trials was strongly encouraged. Many of the recommendations made in the breakout session are in alignment with those made in the other parallel sessions on methodology to assess clinical liver safety data, causality assessment for suspected DILI, and liver safety assessment in special populations (hepatitis B, C, and oncology trials). Nonetheless, a few outstanding issues remain for future consideration.
authors.affiliation: Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA, mark.avigan@fda.hhs.gov.
authors.forename: Mark I
authors.initials: MI
authors.lastname: Avigan
authors.forename: Einar S
authors.initials: ES
authors.lastname: Bjornsson
authors.forename: Markku
authors.initials: M
authors.lastname: Pasanen
authors.forename: Charles
authors.initials: C
authors.lastname: Cooper
authors.forename: Raul J
authors.initials: RJ
authors.lastname: Andrade
authors.forename: Paul B
authors.initials: PB
authors.lastname: Watkins
authors.forename: James H
authors.initials: JH
authors.lastname: Lewis
authors.forename: Michael
authors.initials: M
authors.lastname: Merz
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology*; D002986:Clinical Trials as Topic / Q000379:methods*; D003625:Data Collection / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis; D006801:Humans; D055432:Metabolomics / Q000379:methods; D010597:Pharmacogenetics / Q000379:methods; D040901:Proteomics / Q000379:methods; D012107:Research Design; D018570:Risk Assessment / Q000379:methods; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D015415:Biomarkers